Liqiang Pan

Prof. Liqiang Pan


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2022 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
SJShijie Jin
Shijie Jin
YSYanping Sun
Yanping Sun
XLXiao Liang
Xiao Liang
XGXinyu Gu
Xinyu Gu
JNJiangtao Ning
Jiangtao Ning
LPLiqiang Pan
Liqiang Pan
Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells. The successful application of IgG monoclonal antibodies has inspired the development of various types of therapeutic antibodies, such as antibody fragments, bispecific antibodies, and antibody derivatives (e.g., antibody–drug conjugates and immunocytokines). The miniaturization and multifunctionalization of antibodies are flexible and viable strategies for diagnosing or treating malignant tumors in a complex tumor environment. In this review, we summarize antibodies of various molecular types, antibody applications in cancer therapy, and details of clinical study advances. We also discuss the rationale and mechanism of action of various antibody formats, including antibody–drug conjugates, antibody–oligonucleotide conjugates, bispecific/multispecific antibodies, immunocytokines, antibody fragments, and scaffold proteins. With advances in modern biotechnology, well-designed novel antibodies are finally paving the way for successful treatments of various cancers, including precise tumor immunotherapy, in the clinic.

3 September 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
JFJiansheng Fan
Jiansheng Fan
XZXinlei Zhuang
Xinlei Zhuang
XYXiaoyue Yang
Xiaoyue Yang
YXYingchun Xu
Yingchun Xu
ZZZhan Zhou
Zhan Zhou
SCShuqing Chen
Shuqing Chen

1 October 2021 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
XYXiaoyue Yang
Xiaoyue Yang
JFJiansheng Fan
Jiansheng Fan
YWYue Wu
Yue Wu
ZMZhiming Ma
Zhiming Ma
JHJin Huang
Jin Huang
SCShuqing Chen
Shuqing Chen

30 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
XZXinlei Zhuang
Xinlei Zhuang
ZWZhe Wang
Zhe Wang
JFJiansheng Fan
Jiansheng Fan
XBXuefei Bai
Xuefei Bai
YXYingchun Xu
Yingchun Xu
LPLiqiang Pan
Liqiang Pan
Acquired resistance to cetuximab in colorectal cancers is partially mediated by the acquisition of mutations located in the cetuximab epitope in the epidermal growth factor receptor (EGFR) ectodomain and hinders the clinical application of cetuximab. We develop a structure-guided and phage-assisted evolution approach for cetuximab evolution to reverse EGFRS492R- or EGFRG465R-driven resistance without altering the binding epitope or undermining antibody efficacy. Two evolved cetuximab variants, Ctx-VY and Ctx-Y104D, exhibit a restored binding ability with EGFRS492R, which harbors the most common resistance substitution, S492R. Ctx-W52D exhibits restored binding with EGFR harboring another common cetuximab resistance substitution, G465R (EGFRG465R). All the evolved cetuximab variants effectively inhibit EGFR activation and downstream signaling and induce the internalization and degradation of EGFRS492R and EGFRG465R as well as EGFRWT. The evolved cetuximab variants (Ctx-VY, Ctx-Y104D and Ctx-W52D) with one or two amino acid substitutions in the complementarity-determining region inherit the optimized physical and chemical properties of cetuximab to a great extent, thus ensuring their druggability. Our data collectively show that structure-guided and phage-assisted evolution is an efficient and general approach for reversing receptor mutation-mediated resistance to therapeutic antibody drugs.

13 March 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
YSYanping Sun
Yanping Sun
LZLinling Zhou
Linling Zhou
XGXinyu Gu
Xinyu Gu
JZJiaqi Zhao
Jiaqi Zhao
JBJie Bi
Jie Bi
LPLiqiang Pan
Liqiang Pan
Background: Clinical trials have demonstrated the efficacy of bispecific antibodies in eliciting potent antitumor responses by redirecting T cells to target cancer cells, particularly for the treatment of hematologic malignancies. However, their efficacy against solid tumors is limited by intratumoral T-cell dysfunction and inadequate persistence. The co-stimulatory domains of 4-1BB, OX40, and CD28 are most widely used in engineering chimeric antigen receptor T-cells to augment T-cell responses. Methods: In this study, we designed three co-stimulatory trispecific T cell-engaging antibodies (TriTCEs) that target Prostate-specific membrane antigen, CD3, and an additional co-stimulatory receptor(OX40, 4-1BB, or CD28). We conducted comparative profiling of the attributes of distinct co-stimulatory signals to T-cell functions in prostate cancer models. Results: Co-stimulatory trispecific T-cell engagers enhance T-cell activation, proliferation, and display tumor cell-killing activity in vitro. These trispecific antibodies further boosted antitumor activity in humanized mouse xenograft models and increased the infiltration of CD45+ immune cells into solid tumors. Specifically, TriTCE-4-1BB and TriTCE-CD28 selectively promoted the expansion of effector memory T cells and increased the presence of CD4+ T cells more than TriTCE-OX40. T cells stimulated with TriTCE-4-1BB exhibited reduced exhaustion. Furthermore, T cells treated with co-stimulatory trispecific antibodies demonstrated enhanced metabolic activity characterized by increased oxidative phosphorylation and elevated glycolysis. Conclusions: Collectively, incorporating co-stimulatory receptor targeting domains represents a potentially effective strategy to unlock the full therapeutic potential of T-cell-engaging antibodies for the treatment of solid tumors.

6 November 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
LZLiujuan Zhou
Liujuan Zhou
JBJie Bi
Jie Bi
SCShenghai Chang
Shenghai Chang
ZBZhaoshuai Bai
Zhaoshuai Bai
JYJunqi Yu
Junqi Yu
LPLiqiang Pan
Liqiang Pan